Exercise remains a key component of nonalcoholic fatty liver disease (NAFLD) treatment.
The mechanisms that underpin improvements in NAFLD remain the focus of much …

Lipotoxicity is a phenomenon of lipid-induced cellular injury in nonadipose tissue. Excess of
free saturated fatty acids (SFAs) contributes to hepatic injury in nonalcoholic fatty liver …

Abstract Background and Aims Thyroid axis is currently under investigation as a therapeutic
target in metabolic dysfunction‐associated steatotic liver disease (MASLD). Thyroid function …

Abstract Purpose of Review Metabolic dysfunction–associated steatotic liver disease
(MASLD) and its aggressive form, metabolic dysfunction-associated steatohepatitis (MASH) …

Thyroid hormone action is involved in virtually all physiological processes. It is well known
that the liver and thyroid are intimately linked, with thyroid hormone playing important roles …

Patients with inflammatory liver diseases, particularly alcohol-associated liver disease and
metabolic dysfunction-associated fatty liver disease (MAFLD), have higher incidence of …

Non-alcoholic fatty liver disease (NAFLD) is a burgeoning global public health distress, with
an estimated 25% of the world population affected. Despite the increasing prevalence and …

Thyroid hormone receptor beta (TRβ) is a recognized tumor suppressor in numerous solid
cancers. The molecular signaling of TRβ has been elucidated in several cancer types …

The onset of metabolic dysfunction-associated steatohepatitis (MASH) or non-alcoholic
steatohepatitis (NASH) represents a tipping point leading to liver injury and subsequent …

Background Anaplastic thyroid cancer (ATC) is one of the most lethal endocrine cancers,
with an average survival time of six months after diagnosis. These aggressive tumors have …